Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 97.35M P/E - EPS this Y 50.80% Ern Qtrly Grth -
Income -73.79M Forward P/E -1.26 EPS next Y -31.90% 50D Avg Chg -12.00%
Sales - PEG -0.17 EPS past 5Y - 200D Avg Chg 8.00%
Dividend N/A Price/Book 0.60 EPS next 5Y 34.60% 52W High Chg -64.00%
Recommedations 1.40 Quick Ratio 4.63 Shares Outstanding 58.13M 52W Low Chg 125.00%
Insider Own 20.49% ROA -26.10% Shares Float 38.49M Beta 1.51
Inst Own 29.86% ROE -51.51% Shares Shorted/Prior 2.70M/1.34M Price 2.47
Gross Margin - Profit Margin - Avg. Volume 390,661 Target Price 8.00
Oper. Margin - Earnings Date May 11 Volume 151,411 Change -3.89%
About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc. News
03/28/24 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/27/24 Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
03/21/24 Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges
03/21/24 Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
03/13/24 Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
03/07/24 Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
03/05/24 Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
02/27/24 Pyxis Oncology Announces $50 Million Private Placement
11/28/23 Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
11/07/23 Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
09/27/23 Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
09/14/23 Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc
08/31/23 Pyxis Oncology to Participate in Two Upcoming Investment Conferences
08/23/23 Pyxis Oncology Successfully Completes Acquisition of Apexigen
08/11/23 Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
08/01/23 Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
05/30/23 Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
05/24/23 Pyxis Oncology to Acquire Apexigen
05/11/23 Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
PYXS Chatroom

User Image ViractaTrader77 Posted - 2 days ago

You do the math if a suitor bids $1.8 Billion for Sutro what’s the ROI??? https://twitter.com/BiotechTVHQ/status/1775900116924448891/mediaViewer?currentTweet=1775900116924448891&currentTweetUser=BiotechTVHQ $STRO $ELEV $PYXS $VINC

User Image ViractaTrader77 Posted - 4 days ago

$IMGN $AMAM $VKTX $PYXS Trading beneath cash, tons of big pharma partnerships. 2 folate ADCs acquired in past 18 mos for $12 billion combined. Could be next major adc acquisition target. Do your homework on Sutro https://x.com/BiotechTVHQ/status/1775900116924448891

User Image Stocksrunner Posted - 5 days ago

Today's analyst upgrades to watch: $AAPL - Analysts foresee a 20% upside potential despite growth concerns. $PYXS - Analysts anticipate a potential rally of 61.29%. $RMBL - With a 61.29% potential rally as per analysts. $SHIP - Analysts predict a surge of 45.74% for SHIP. Stay informed with analyst insights! 🚀 https://stocksrunner.com/upgrades

User Image Dtwod7474 Posted - 5 days ago

$VINC way oversold. Low float. Plenty of cash with atm to get thru next results. Only takes a couple whales and this share price quadruples. Yes, quadruples and would still be only have of its $9 high a few weeks ago lol. No brainer! $PYXS $PFIZER.NSE

User Image jerry81 Posted - 5 days ago


User Image ViractaTrader77 Posted - 6 days ago

$STRO $PYXS $FUSN $AMAM Sutro Bio could be next on big Pharma list. Immunogen and Profound Bio are similar to sutro’s lead ADC Luvelta in that it binds to the folate receptor. https://www.investopedia.com/genmab-buys-profoundbio-for-usd1-8b-to-boost-oncology-portfolio-8624021

User Image cupandhandleguy Posted - 1 week ago

$PYXS inverse head and shoulder

User Image ViractaTrader77 Posted - 1 week ago

$STRO Point72 just acquired 5.7 million shares of ADC biotech Sutro Biopharma. Stocks trading around cash. Similar ADC to drug Abbvie bought for $10 billion. https://www.sec.gov/Archives/edgar/data/1382101/000090266424002770/p24-1385sc13g.htm $ADCT $PYXS $IOVA

User Image internetentrepreneur Posted - 1 week ago

$PYXS 10 dollars next week?

User Image ViractaTrader77 Posted - 1 week ago

@telomerase I am a change manager. Fund managers I guess field calls from bankers all day and look at Bloomberg terminals. I am into ADC stocks. The niche is a money maker. Pyxis, Vincerx, Sutro All these were totally misplaced in January. They all went up 500%… Sutro only one that didn’t. Could hit $10. Vincerx might hit $10 on Monday. $PYXS $VINC $STRO

User Image ViractaTrader77 Posted - 1 week ago

$STRO Trading at cash in hottest sector in biotech. Antibody Drug Conjugates Deals with Ispen Pharma and Astellas (Ambrx had deal with Astellas as well they just got acquired for $2 billion) sl Sutro worth $8.50 minimum biotech value fund in large $PYXS $ADCT $ELEV

User Image commoncentsinvestor Posted - 1 week ago

$PYXS ONE TO CHECK OUT FOR BIG GAINS IN 2024 Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.

User Image Dtwod7474 Posted - 1 week ago

$TCBP extremely low float. This could skyrocket way more today. $VINC Check it out friends. $PYXS . So much potential and shorts are getting roasted today. $ASTRAZEN.NSE https://finance.yahoo.com/news/tcbp-announces-execution-non-binding-123000295.html

User Image AllzGood Posted - 1 week ago

$PYXS So much for waiting for a pullback. This thing just keeps on truckin'.

User Image ViractaTrader77 Posted - 1 week ago

$STRO who will end up acquiring Sutro (astellas partnered with both ambrx and Sutro and JNJ just bought them for $2 bil) Ispen Pharma or astellas??. Sutro trading beneath cash and they have 1.6 million shares of Vaxcyte. Both very large pharmaceutical companies. Ispen just infused $25 million investment in Sutro’s stock and upon milestone putting in another $10 million. And they acquired the adc for $50 million upfront+ 800 mil in milestones. Since Abbvie acquired $IMGN for $10 billion their might be a white knight like astellas that comes in and buys Sutro for their Ovarian ADC. Astellas already gave Sutro $90 million. $PYXS $IOVA $IBRX

User Image Stockswethoughttheywere Posted - 2 weeks ago


User Image Relee187200 Posted - 2 weeks ago

$PYXS Weird trading.

User Image internetentrepreneur Posted - 2 weeks ago

$PYXS back to 3 dollars

User Image internetentrepreneur Posted - 2 weeks ago

$PYXS why did it crash as soon as i bought?

User Image ViractaTrader77 Posted - 2 weeks ago

Looks like Sutro can easily hit $7.50 per share. B of A must have sold some $5.18 shares to flippers when they are done I expect this to fly with the infusion of $165,000,000 yesterday between Ispen and the fundamental healthcare investors. $STRO $PYXS $VKTX $NUVB

User Image internetentrepreneur Posted - 2 weeks ago

$PYXS why is this flying?

User Image AmbushPredator Posted - 2 weeks ago


User Image AmbushPredator Posted - 2 weeks ago

$PYXS told you!

User Image Capitulation_0 Posted - 2 weeks ago

$PYXS wowza.. what a bounce

User Image internetentrepreneur Posted - 2 weeks ago

$PYXS whats happening? Can we get to 20 ?

User Image Relee187200 Posted - 2 weeks ago

$PYXS Any news?? Why up on good volume?

User Image ViractaTrader77 Posted - 2 weeks ago

$PYXS ADC biotech trading sub cash. Check it out Sutro Biopharma Just sold Ror1 antibody for $90 million to Ispen $STRO $ADCT $MRSN

User Image Relee187200 Posted - 2 weeks ago

$PYXS Why moving up??

User Image StefanDrake Posted - 2 weeks ago

$PYXS this stock will make some of you millionaire. Hold $$$$

User Image internetentrepreneur Posted - 2 weeks ago

$PYXS 20 by end of week

Analyst Ratings
HC Wainwright & Co. Buy Apr 10, 24
RBC Capital Outperform Mar 22, 24
HC Wainwright & Co. Buy Mar 22, 24
BTIG Buy Feb 9, 24
Leerink Partners Outperform Jan 23, 24
HC Wainwright & Co. Buy Nov 30, 23
RBC Capital Outperform Sep 5, 23
EF Hutton Buy Jul 31, 23
Credit Suisse Outperform Mar 23, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wadhane Jitendra Chief Accounting Off.. Chief Accounting Officer Sep 27 Buy 1.87 2,500 4,675 226,937 09/27/23
Connealy Pamela Ann CFO and COO CFO and COO Sep 27 Buy 1.8468 6,426 11,868 810,532 09/27/23
Wadhane Jitendra Chief Accounting Off.. Chief Accounting Officer Sep 25 Buy 1.77 5,000 8,850 224,437 09/25/23
Connealy Pamela Ann CFO and COO CFO and COO Sep 25 Buy 1.6703 12,000 20,044 804,106 09/25/23
Wadhane Jitendra Chief Accounting Off.. Chief Accounting Officer Sep 22 Buy 1.7397 2,500 4,349 219,437 09/22/23
Connealy Pamela Ann CFO and COO CFO and COO Sep 22 Buy 1.739 5,000 8,695 792,106 09/22/23
Sullivan Lara President and CEO President and CEO Sep 14 Sell 2.18 8,641 18,837 2,403,882 09/18/23
Sullivan Lara President and CEO President and CEO Sep 11 Sell 2.26 27,917 63,092 2,597,265 09/13/23
PFIZER INC 10% Owner 10% Owner Mar 17 Buy 2.76 1,811,594 4,999,999 5,952,263 03/21/23
Chin Mark Other Other Apr 21 Sell 3.05 1,745,761 5,324,571 04/25/22
Chin Mark Director Director Oct 13 Buy 16 312,500 5,000,000 1,745,761 10/15/21